Meralgia Paresthetica Education and the Anesthesiology Boards

This podcast episode from the NRAP Academy features Dr. David Rosenblum discussing Meralgia Paresthetica, a mononeuropathy affecting the lateral femoral cutaneous nerve. The condition involves entrapment or compression of this purely sensory nerve as it passes under the inguinal ligament near the anterior superior iliac spine, causing burning pain, tingling, and numbness in the anterior lateral thigh.

Key clinical points covered include the nerve's L2-3 origin from the lumbar plexus, common causes such as obesity, tight clothing, pregnancy, and diabetes, and the absence of motor weakness or reflex changes. Diagnosis is primarily clinical, though ultrasound can visualize nerve entrapment effectively.

Treatment approaches range from conservative management including weight loss, avoiding tight clothing, physical therapy, and neuropathic pain medications (gabapentinoids, duloxetine, tricyclics) to interventional procedures. Dr. Rosenblu strongly advocates for ultrasound-guided nerve blocks over fluoroscopic or blind approaches, citing better visualization and reduced risk of nerve trauma. Advanced treatments mentioned include peripheral neuromodulation and cryoablation for refractory cases.

The episode emphasizes that this condition is commonly tested on pain management board examinations (ABA, ABPM, FIPP, osteopathic boards) and can be significantly more painful and disabling than typically appreciated.

Upcoming Courses and Training Opportunities:

• Ultrasound training available at nrappain.org
• Regenerative medicine training courses
• Comprehensive Anestheisia and Question Bank for Pain Management board preparation covering ABA, ABPM, FIPP, and osteopathic examinations
• CME credits available through the platform
• Clinical consultation services available at Dr. Rosenblum's Brooklyn office for patients seeking treatment. Call 718 436 7246 or go to www.AABPpain.com 

Meralgia Paresthetica Education and Clinical Guidance

• Overview:
• Focused on definition, anatomy, diagnosis, management, and board exam relevance for meralgia paresthetica.
• Anatomy and Pathophysiology:
• Nerve: lateral femoral cutaneous nerve (sensory only), typically arising from L2–L3.
• Course: traverses across the iliacus, passes under or through the inguinal ligament just medial to the ASIS, then enters the thigh.
• Sensory distribution: anterolateral thigh; anterior cutaneous division extends toward the knee.
• Etiology and Risk Factors:
• Common contributors: obesity, tight belts or clothing, pregnancy, prolonged sitting, diabetes, prior pelvic or hip surgery.
• Entrapment site: under the inguinal ligament near the ASIS (most frequent).
• Clinical Presentation:
• Symptoms: burning pain, tingling, numbness, dysesthesia localized to the anterolateral thigh.
• Provocation/relief: worse with standing or walking; relief with sitting or hip flexion.
• Neurologic exam: no motor weakness; no reflex changes.
• Diagnosis:
• Primarily clinical; Tinel’s sign over the inguinal ligament may reproduce symptoms.
• EMG and nerve conduction studies are typically normal.
• Ultrasound: superficial nerve, generally easy to visualize, including in obese patients; can identify entrapment.
• Management Recommendations:
• First-line conservative care: weight loss; avoidance of tight belts/clothing; physical therapy; NSAIDs for inflammation.
• Pharmacologic options: gabapentin, pregabalin, duloxetine, tricyclic antidepressants; consider topical analgesic creams (e.g., lidocaine or anti-inflammatory combinations).
• Interventional approach:
• Ultrasound-guided nerve block is strongly recommended; the nerve lies lateral to the sartorius; real-time visualization enables precise, safe injection.
• Avoid fluoroscopic and blind approaches due to risk of further nerve trauma and post-procedure pain.
• Advanced interventions:
• Peripheral neuromodulation may provide benefit in select cases.
• Cryoablation has shown beneficial outcomes for the lateral femoral cutaneous nerve.
• Surgery is rarely required; options include neurolysis, decompression, or neurectomy as a last resort.
• Board Exam Preparation Emphasis:
• Key facts commonly tested:
• Involved nerve: lateral femoral cutaneous nerve.
• Nerve roots: L2–L3 (with population variants).
• Sensory-only nerve; absence of motor deficits.
• Compression site: under the inguinal ligament near the ASIS.
• First-line therapy: conservative measures; refractory cases: ultrasound-guided nerve block.
• Keywords to study: meralgia paresthetica; lateral femoral cutaneous nerve (also called lateral cutaneous nerve of the thigh).
• Practice Considerations:
• Severity: can be profoundly painful and disabling; often underappreciated.
• Referral: clinicians not trained in interventional techniques should refer patients to an interventionalist for diagnosis and treatment.

Decisions and Recommendations

• Ultrasound guidance is the preferred modality for lateral femoral cutaneous nerve interventions, superseding fluoroscopic or blind approaches.
• Rationale: superior visualization, real-time feedback, and reduced risk of nerve trauma and post-procedural pain.

Outreach and Resources

• NRAP Academy resources:
• Ultrasound training, regenerative medicine training, CME credits, and a comprehensive pain board question bank (ABA, ABPM, FIPP, osteopathic, and related exams).
• Clinical availability:
• Patient consultations for meralgia paresthetica offered in Brooklyn at www.AABPpain.com 718 436 7246 .

Project Sync / Status Update Summary

Podcast Episode Overview

• The host discussed Transcutaneous Electrical Nerve Stimulation (TENS) as a recurring pain board topic and reviewed mechanisms, efficacy, and clinical considerations.

• Emphasis that TENS appears on pain boards annually and is a foundational topic from early podcast episodes.

• Board Prep and NRAP Community at PainExam.com or NRAPpain.org
• ABA ABPM ABIPP FIPP Pain Management Board prep, Question Banks, and Virtual Pain Fellowship

Educational Offerings and Events

• Training and Courses:

• Monthly ultrasound courses in New York and upcoming courses in Detroit covering ultrasound-guided regional anesthesia and chronic pain.

• Ultrasound Guided Acute and Chronic Pain course in November near Hollywood/Fort Lauderdale with venue pending confirmation.

• Multiple instructors to offer diverse perspectives; registration via the CME calendar at nrappain.org.

• Conferences and Teaching:

• New York–New Jersey Pain Conference in November (hosted by Soudir Duwan).

• ISPN conference in London next week, with ultrasound teaching participation by the host.

• Community and Coaching:

• Private coaching and shadowing opportunities available; contact via newsletter replies.

• Access to the NRAP community forum upon signup at nrappain.org for discussions on neuromodulation, regional anesthesia, and pain.

TENS: Mechanisms and Parameters

• Device and Parameters:

• TENS delivers adjustable pulse frequency and intensity; configurations include low (<10 Hz), high (>50–100+ Hz), and mixed frequencies.

• Mechanisms of Analgesia:

• Activation of large-diameter, non-noxious A-beta afferent fibers in the periphery, driving descending inhibitory pathways and reducing hyperalgesia.

• Board-relevant point: selective activation of A-beta fibers is frequently tested.

• Central effects:

• Reduces central excitability and nociceptive dorsal horn neuron activity in uninjured and injured models.

• Frequency-dependent opioid receptor mediation:

• High-frequency analgesia blocked by delta receptor antagonists.

• Low-frequency analgesia blocked by mu receptor antagonists (spinal cord and rostral ventral medulla).

• Additional receptor involvement: muscarinic M1/M3, GABA-A, and cannabinoid (CB1) receptors; blockade reduces or prevents TENS analgesia depending on frequency.

• Peripheral effects:

• High-frequency TENS reduces injury-related increases in substance P in DRG neurons.

• Blockade of peripheral opioid and CB1 receptors can prevent analgesia from both low- and high-frequency TENS.

• Clinical dosing considerations:

• Adequate dosing (timing, frequency of use, intensity achieving strong but non-painful paresthesia) influences efficacy.

• Analgesia has rapid onset/offset and may require repeated administration throughout the day for sustained relief.

Evidence and Efficacy Summary

• Clinical experience suggests potential adjunctive benefit for acute pain, but systematic reviews are conflicting; more rigorous studies are needed.

• For board preparation, the critical takeaway is A-beta fiber activation.

Key Takeaways for Board Prep

• TENS targets large-diameter non-noxious A-beta afferents to reduce nociceptive signaling.

• High-frequency TENS: analgesia mediated via delta opioid receptors; blocked by delta antagonists.

• Low-frequency TENS: analgesia mediated via mu opioid receptors; blocked by mu antagonists in spinal cord and RVM.

• Additional receptor systems influencing TENS efficacy include muscarinic (M1/M3), GABA-A, and CB1.

Action Items

David Rosenblum, MD, currently serves as the Director of Pain Management at Maimonides Medical Center and AABP Integrative Pain Care.  As a member of the Department of Anesthesiology, he is involved in teaching, research, CME activities, and was key faculty in developing the anesthesiology residency's regional anesthesia block rotation, as well as institutional wide acute and chronic pain management protocols to ensure safe and effective pain management. He currently is a managing partner in a multi-physician private pain practice, AABP Integrative Pain Care, located in Brooklyn, NY. He is one of the earliest interventional pain physicians to integrate ultrasound guidance to improve the safety and accuracy of interventional pain procedures.

Patients can go to www.AABPpain.com or call 718 436 7246

Awards

New York Magazine: Top Doctors: 2016, 2017, 2018, 2021, 2022, 2023, 2024, 2025

Schneps Media: 2015, 2016, 2017, 2019, 2020

Top Doctors New York Metro Area (digital guide): 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023 2025

Schneps Media - Brooklyn Courier Life: 2021, 2022, 2023

References 

Johnson M. Transcutaneous Electrical Nerve Stimulation: Mechanisms, Clinical Application and Evidence. Rev Pain. 2007 Aug;1(1):7-11. doi: 10.1177/204946370700100103. PMID: 26526976; PMCID: PMC4589923.

Vance, C.G.T.; Dailey, D.L.; Chimenti, R.L.; Van Gorp, B.J.; Crofford, L.J.; Sluka, K.A. Using TENS for Pain Control: Update on the State of the Evidence. Medicina 2022, 58, 1332. https://doi.org/10.3390/medicina58101332

#painnyc #painbrooklyn #prpbrooklyn #prpspine #regionalanesthsia #pccwindsor #paincareclinicswindsor #painwindsorontario #paindocwindsorontarior #paincareclinics #prpwindsorontario #prp 

Podcast Summary

This episode of the Pain Exam Podcast, hosted by Dr. David Rosenblum, discusses an interesting article about Ketorolac injections for musculoskeletal conditions. The podcast covers:

• Ketorolac is an NSAID that provides analgesic and anti-inflammatory effects through inhibition of prostaglandin synthesis

• Multiple studies comparing Ketorolac injections to corticosteroids and hyaluronic acid for various conditions

• Research shows Ketorolac injections are equally effective as corticosteroids for subacromial conditions, adhesive capsulitis, carpal-metacarpal joint issues, and hip/knee osteoarthritis

• Ketorolac may be a safer alternative to steroids for certain patients, though it has its own contraindications for those with renal, gastrointestinal, or cardiovascular disease

• Dr. Rosenblum considers the potential of using Ketorolac injections directly at pain sites rather than intramuscularly

Upcoming Courses and Conferences

• Ultrasound courses in New York and Costa Rica (check unwrappedpain.org)

• Private ultrasound sessions available

• Dr. Rosenblum will be speaking at Pain Week about ultrasound in pain practice and PRP

• Presenting at a primary care conference in London

• Teaching ultrasound at ISPN

• LAPS  conference in Chile (Dr. Rosenblum won't attend this year)

• Ketorolac Injections: An Effective Alternative for Musculoskeletal Pain Management

  Musculoskeletal conditions such as bursitis, adhesive capsulitis, and osteoarthritis affect millions and often require injectable therapies to reduce pain and inflammation. Traditionally, corticosteroid injections have been the mainstay treatment. However, concerns over side effects like tendon rupture, cartilage damage, and systemic hyperglycemia have prompted exploration of alternatives. A recent narrative review by Kiel et al. (2024) highlights ketorolac—a parenteral nonsteroidal anti-inflammatory drug (NSAID)—as a promising substitute for corticosteroids in musculoskeletal injections.

  

  Warning: OFF Label use of Ketorolac discussed. Please consult your physician.

  See full article  for details.

  Subacromial Ketorolac Injections for Shoulder Pain

  Subacromial bursitis and impingement syndrome are common causes of shoulder pain and disability. Several randomized controlled trials have shown that subacromial ketorolac injections provide pain relief and functional improvement comparable to corticosteroids:

  • Goyal et al. demonstrated significant reductions in pain scores after subacromial injection of 60 mg ketorolac versus 40 mg methylprednisolone, with no difference in outcomes between groups.
  • Taheri et al. found similar short-term pain relief at 1 and 3 months with either ketorolac or corticosteroid subacromial injections.
  • Kim et al. reported equivalent clinical improvement in rotator cuff syndrome patients receiving ketorolac or triamcinolone injections.
  • Min et al. noted ketorolac led to better forward flexion and patient satisfaction at 4 weeks compared to corticosteroids.

  These studies support ketorolac as an effective agent for subacromial injection, offering an alternative for patients where corticosteroid use is limited.

  Intra-articular Ketorolac Injections for Adhesive Capsulitis and Osteoarthritis

  Adhesive capsulitis (frozen shoulder) and osteoarthritis of the hip, knee, and carpometacarpal joint are often treated with intra-articular corticosteroids. Ketorolac injections have shown comparable efficacy in these conditions:

  • Akhtar et al. found intra-articular ketorolac significantly reduced shoulder pain at 4 weeks in adhesive capsulitis compared to hyaluronic acid.
  • Ahn et al. reported similar pain relief between intra-articular ketorolac and corticosteroid injections in adhesive capsulitis, with ketorolac providing superior shoulder mobility at 3 and 6 months.
  • Koh et al. showed that adding ketorolac to hyaluronic acid injections in carpometacarpal osteoarthritis resulted in faster onset of pain relief compared to hyaluronic acid alone.
  • Park et al. observed equivalent functional improvements with intra-articular ketorolac or corticosteroids in hip osteoarthritis.
  • Jurgensmeier et al. demonstrated similar symptom improvement at 1 and 3 months post-injection for ketorolac and triamcinolone in hip and knee osteoarthritis.
  • Xu et al. and Bellamy et al. confirmed ketorolac’s comparable pain relief and functional benefits to corticosteroids for knee osteoarthritis, with ketorolac being more cost-effective.
  • Lee et al. noted quicker pain reduction with intra-articular ketorolac combined with hyaluronic acid versus hyaluronic acid alone in knee osteoarthritis.

  aSafety and Pharmacologic Considerations

  Ketorolac’s anti-inflammatory action stems from cyclooxygenase inhibition, reducing prostaglandin synthesis. Its half-life is approximately 5.2–5.6 hours, and it is metabolized in the liver. Unlike corticosteroids, ketorolac avoids systemic hyperglycemia and cartilage damage risks. Animal and in vitro studies suggest ketorolac may protect cartilage by inhibiting inflammatory cytokines.

  While gastrointestinal, renal, and cardiovascular risks associated with NSAIDs remain considerations, localized intra-articular and subacromial ketorolac injections may limit systemic exposure and adverse effects. Mild, transient post-injection pain has been reported but resolves without intervention.

  Conclusion

  Ketorolac injections, administered intra-articularly or subacromially, are a safe, effective, and economical alternative to corticosteroids for managing common musculoskeletal conditions. Their comparable efficacy in reducing pain and improving function, combined with a more favorable side effect profile, makes ketorolac an appealing option for clinicians and patients alike. Further research is warranted to fully elucidate long-term safety and optimal dosing strategies.

  ---

  FAQS

  Ketorolac Injections for Musculoskeletal Conditions: Frequently Asked Questions

  Musculoskeletal pain from conditions like bursitis, adhesive capsulitis, and osteoarthritis often requires injectable treatments. Ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is emerging as a promising alternative to corticosteroids. Below are common questions and answers based on a recent narrative review by Kiel et al. (2024).

  ---

  1. What is ketorolac and how does it work?

  Ketorolac is a parenteral NSAID that reduces pain and inflammation by inhibiting cyclooxygenase enzymes, which decreases prostaglandin synthesis. It can be administered orally, intramuscularly, intravenously, or by injection directly into joints or around bursae.

  ---

  2. How effective is ketorolac for musculoskeletal conditions?

  Studies show ketorolac injections provide significant pain relief and functional improvement comparable to corticosteroids in conditions like:

  • Subacromial bursitis and shoulder impingement (subacromial injections)
  • Adhesive capsulitis (frozen shoulder) (intra-articular injections)
  • Osteoarthritis of the hip, knee, and thumb carpometacarpal joint (intra-articular injections)

  ---

  3. What evidence supports subacromial ketorolac injections?

  Randomized controlled trials found:

  • Goyal et al. and Taheri et al. reported similar pain reduction and functional outcomes between ketorolac and corticosteroids for subacromial injections.
  • Kim et al. and Min et al. observed comparable or better patient satisfaction and shoulder mobility with ketorolac versus corticosteroids.

  ---

  4. How does intra-articular ketorolac compare to corticosteroids for adhesive capsulitis?

  • Akhtar et al. showed ketorolac reduced shoulder pain more than hyaluronic acid.
  • Ahn et al. found ketorolac and corticosteroids equally effective for pain relief, with ketorolac providing better shoulder mobility at 3 and 6 months.

  ---

  5. What about ketorolac for osteoarthritis?

  • Ketorolac combined with hyaluronic acid provided faster pain relief than hyaluronic acid alone in thumb carpometacarpal joint osteoarthritis (Koh et al.).
  • Intra-articular ketorolac had similar efficacy to corticosteroids in hip (Park et al., Jurgensmeier et al.) and knee osteoarthritis (Bellamy et al., Xu et al.).
  • Ketorolac injections were more cost-effective compared to corticosteroids (Bellamy et al.).

  ---

  6. Are ketorolac injections safe?

  Ketorolac's side effects are similar to other NSAIDs, mainly involving gastrointestinal, renal, and cardiovascular risks. However, localized intra-articular and subacromial injections may reduce systemic exposure. Animal studies suggest ketorolac does not harm cartilage and may protect against inflammatory damage. Mild, transient local pain post-injection is possible but usually resolves without treatment.

  ---

  7. What are the limitations of ketorolac use?

  Ketorolac is not suitable for patients with:

  • Renal impairment
  • Gastrointestinal ulcers or bleeding risk
  • Cardiovascular disease or hypertension
  • NSAID hypersensitivity, especially in asthma or chronic urticaria patients

  Clinicians should assess individual risks before choosing ketorolac injections.

  ---

  8. How does ketorolac’s pharmacokinetics affect its use?

  Ketorolac has a plasma half-life of about 5.2 to 5.6 hours and is metabolized in the liver. Pharmacokinetics for subcutaneous or intra-articular administration are less defined but systemic absorption occurs. Its relatively short half-life supports repeated dosing if needed.

  ---

  9. Why consider ketorolac over corticosteroids?

  Ketorolac avoids corticosteroid-associated risks such as tendon rupture, cartilage damage, and steroid-induced hyperglycemia. It is also more cost-effective, making it a favorable option for patients and healthcare systems.

  ---

  10. What further research is needed?

  More large-scale, long-term studies are needed to fully understand ketorolac’s intra-articular effects, optimal dosing, and safety profile compared to corticosteroids and other treatments.

  ---

  Summary:
  Ketorolac injections, whether intra-articular or subacromial, offer a safe, effective, and economical alternative to corticosteroids for managing various musculoskeletal conditions. This makes ketorolac an important option in pain management and inflammation control.

   

   

  Reference:

  Kiel J, Applewhite AI, Bertasi TGO, Bertasi RAO, Seemann LL, Costa LMC, Helmi H, Pujalte GGA. Ketorolac Injections for Musculoskeletal Conditions: A Narrative Review. Clinical Medicine & Research. 2024;22(1):19-27. DOI: https://doi.org/10.3121/cmr.2024.1847

  

  Disclaimer: This Podcast, website and any content from NRAP Academy (PMRexam.com) otherwise known as Qbazaar.com, LLC is  for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. Professionals should conduct their own fact finding, research, and due diligence to come to their own conclusions for treating patients. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

   

Summary

The video covers a conversation between Dr. David Rosenblum and Dr. Hamed Sadeghipour, discussing board preparation experiences and the current state of pain management practice. Dr. Rosenblum begins by announcing upcoming events, including a May 17th ultrasound course in New York City and his lectures at various conferences. He also mentions shadowing opportunities at his office. Dr. Sadeghipour shares his board preparation experience, discussing three main resources he used: Huntoon book (800 questions), Board Vitals (700 questions), and Pain Exam. He achieved notably high scores using these resources. Regarding his current practice, Dr. Sadeghipour describes working both in academic anesthesia (40-50% time) and private pain practice, managing four offices with four nurse practitioners  The discussion then shifts to the changing landscape of pain management, with both doctors noting concerning trends: increasing focus on surgery center procedures over office-based ones due to reimbursement differences, the challenge of maintaining competency in advanced procedures, and competition from non-specialists entering the field. They also discuss the future of the specialty, suggesting it's moving toward becoming a hybrid of neurosurgery and orthopedic surgery with traditional pain management procedures.

For pain medicine Board Prep go to NRAPpain.org

For ultraound training go to NRAP Academy

Highlights

Introduction and Upcoming Events

Dr. Rosenblum introduces the podcast and announces several upcoming events, including an ultrasound course in New York City on May 17th, appearances at ASPN and Pain Week conferences, and opportunities for shadowing at his practice.

Board Preparation Experience Discussion

Dr. Sadeghipour details his board preparation strategy using three main resources: Huntoon book (800 questions), Board Vitals (700 questions), and Pain Exam(700 questions videos, lectures, ultrasound training, regenerative medicine training and more). He explains the strengths and limitations of each resource and mentions achieving exceptionally high scores.

Current Practice Structure

Dr. Sadeghipour describes his dual practice model: 

Evolution of Pain Management Practice

Both doctors discuss the shifting landscape of pain management, noting increased focus on surgery center procedures, reimbursement challenges, and competition from non-specialists. They address concerns about fellowship training adequacy and the financial pressures affecting new practitioners.

Future of Pain Management Specialty

The discussion concludes with perspectives on the specialty's future, suggesting it's evolving toward a combination of minimally invasive spine surgery and traditional pain management, with concerns about maintaining specialty integrity and the need for stronger regulatory oversight.

Journal Club:  Treating Degenerative Disc Disease with Leukocyte Rich PRP

Dr. Rosenblum discusses an article written by Dr. Gregory Lutz describing Leukocyte RIch PRP's role in treating Degenerative Disc Disease and the theory that there is an infectious disease component to disc injury. 

Dr. Lutz describes multiple articles, as well as anectodal experience in which bacterial infectious was demonstrated in pathological discs, and PRP was successful in alleviating symptoms, modic changes and improved clinical as well as radiographic appearance.

References

Lutz, Gregory E. "Intradiscal Leukocyte Rich Platelet Rich Plasma for Degenerative Disc Disease." Physical Medicine and Rehabilitation Clinics of North America 34.1 (2023): 117-133.https://www.binasss.sa.cr/bibliotecas/bhm/feb23/61.pdf

Carpal Tunnel Syndrome

 In this episode, we will be discussing Carpal Tunnel Syndrome, a common condition that affects millions of people worldwide. But before we dive into the topic, we want to tell you about a great opportunity to advance your medical knowledge through the NRAP Academy CME courses offered on our website.

Dr. Rosenblum interviews SmartAppt Creator, Albert Pilip, MD on his Doctor-Patient Friendly App that takes the Pain out of Scheduling Appointments.

Sign up to my latest affiliates' answer to Zocdoc

Ultrasound Course Schedule- Winter 2021 Released- Join our newsletter for updates!

• 4 Hour CME Webinar Access
• 2 Hour Hands on (in Person in NY or via Zoom)
• Tips on Safe Integration into your Practice
• Billing

Learn Brachial Plexus, Femoral, Sciatic, Saphenous, Genicular, IPACK, TAP, Paravertebral, Inercostal, Sacroiliac, Peripheral nerves, Iliioinguinal, Cluneal nerve blocks and more!

Dr. Rosenblum summarizes CMS' Outreach and Educations against Opioid Misuse. 

Click here for the full article

NMDA receptor for the boards (ketamine, allodynia, etc)

Reference

The Role of N-Methyl-d-Aspartate (NMDA) Receptors in Pain: A Review

Petrenko, Andrei B. MD; Yamakura, Tomohiro MD, PhD; Baba, Hiroshi MD, PhD; Shimoji, Koki MD, PhD, FRCA

Dr. Rosenblum interviews Dr. Paul about the process of obtaining a job in the age of the Affordable Care Act.

Discussed:

Contracts

Partnership tracts

Fellowship

For more information on Pain Management Topics and keywords

AnesthesiaExam Podcast 

For Board Review and Practice Management Updates TEXT the word 

ANESTHESIAEXAM to the number 33444 

For more information, CME credit and MOCA and Primary Board Prep,

For more information, CME credit and MOCA and Primary Anesthesiology Board Prep,

Go to AnesthesiaExam.com

For Basic and Advanced Anesthesia Exam Review, 

Go to ABAStagedExams.com

For CRNA Board Prep, go to CRNABoardPrep.com

For the Pediatric Anesthesiology Board Review, Go to PedsAE.com

David Rosenblum, MD specializes in Pain Management and is the Director of Pain Management at Maimonides Medical Center and AABP Pain Managment

For evaluation and treatment of a Painful Disorder, go to www.AABPPain.com

Go to PainExam.com

David Rosenblum, MD specializes in Pain Management and is the Director of Pain Management at Maimonides Medical Center and AABP Pain Managment

For evaluation and treatment of a Painful Disorder, go to www.AABPPain.com

718 436 7246

DISCLAIMER: Doctor Rosenblum IS HERE SOLELY TO EDUCATE, AND YOU ARE SOLELY RESPONSIBLE FOR ALL YOUR DECISIONS AND ACTIONS IN RESPONSE TO ANY INFORMATION CONTAINED HEREIN. This podcasts is not intended as a substitute for the medical advice of physician to a particular patient or specific ailment. 

You should regularly consult a physician in matters relating to yours or another’s health.  You understand that this podcast is not intended as a substitute for consultation with a licensed medical professional. 

Copyright © 2015 QBazaar.com, LLC  All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, recording or otherwise, without the prior written permission of the author.

On this Podcast

ICD 10 Preparation Free Version with all of the details to prepare you for the new system

Wrong sided procedure

RSD

Chronic pain

CRPS, etc

 For the full version, check out...

The PainExam Podcast

Download our Free iphone App!

Download our Free Android App!

Subscription required for Premium Access

For more information on Pain Management Topics and keywords

AnesthesiaExam Podcast 

For more information, CME credit and MOCA and Primary Board Prep,

Go to AnesthesiaExam.com

For Basic and Advanced Anesthesia Exam Review, 

Go to ABAStagedExams.com

For the Pediatric Anesthesiology Board Review, Go to PedsAE.com

David Rosenblum, MD specializes in Pain Management and is the Director of Pain Management at Maimonides Medical Center and AABP Pain Managment

For evaluation and treatment of a Painful Disorder, go to www.AABPPain.com

718 436 7246

DISCLAIMER: Doctor Rosenblum IS HERE SOLELY TO EDUCATE, AND YOU ARE SOLELY RESPONSIBLE FOR ALL YOUR DECISIONS AND ACTIONS IN RESPONSE TO ANY INFORMATION CONTAINED HEREIN. This podcasts is not intended as a substitute for the medical advice of physician to a particular patient or specific ailment. 

You should regularly consult a physician in matters relating to yours or another’s health.  You understand that this podcast is not intended as a substitute for consultation with a licensed medical professional. 

Copyright © 2015 QBazaar.com, LLC  All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, recording or otherwise, without the prior written permission of the author.

 Reference

https://www.codeitrightonline.com/ciri/understanding-icd-10-cm-episode-of-care-7th-character-extensions.html

ICD 10-CM. The Complete Official Draft Code set. 2014